Summary & Overview
HCPCS J3398: Voretigene Neparvovec-Rzyl Injection, 1 Billion Vector Genomes
HCPCS Level II code J3398 identifies the administration of voretigene neparvovec-rzyl at a dose of 1 billion vector genomes, a gene therapy for select inherited retinal diseases. Nationally, this code captures use of a high-cost, specialty biologic delivered via an ophthalmic injection procedure, with implications for coverage policy, prior authorization, and site-of-service billing. The analysis addresses payer approaches to coverage, billing nuances for hospital outpatient departments and ambulatory surgical centers, and the clinical context for use.
Key payers included in the discussion are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of typical billing patterns, common modifier usage, and service-line considerations relevant for facility and professional claims. The publication outlines benchmark topics such as authorization requirements, documentation expectations tied to clinical indication, and procedural settings where the product is administered. It also highlights national policy trends affecting gene therapies, coding clarity for HCPCS Level II reporting, and operational considerations for integrating high-cost injectable biologics into revenue cycle workflows.
Data not available in the input is noted where specific payer policies, associated taxonomies, ICD-10 diagnoses, and related codes are not provided.
Billing Code Overview
HCPCS Level II code J3398 describes the injection of voretigene neparvovec-rzyl, dosed as 1 billion vector genomes. This entry represents a gene therapy product administered by injection for inherited retinal disorders where voretigene neparvovec-rzyl is indicated.
Service type: drug administration (intravitreal/subretinal gene therapy injection)
Typical site of service: hospital outpatient department or ambulatory surgical center, where sterile operating conditions and specialized ophthalmic surgical teams are available.
Clinical & Coding Specifications
Clinical Context
A typical patient is a pediatric or young adult with confirmed biallelic RPE65 mutation-associated retinal dystrophy presenting with severe visual impairment progressing to legal blindness. The clinical workflow begins with genetic testing confirming two pathogenic variants in the RPE65 gene and baseline ophthalmic assessment including best-corrected visual acuity, visual field testing (Goldmann or automated perimetry adapted for low vision), optical coherence tomography (OCT), fundus photography, and full ophthalmic examination under anesthesia if needed. Pre-procedural counseling includes discussion of risks, benefits, alternatives, and informed consent from the patient or guardian. The procedural setting is an ambulatory surgical center or hospital operating room with ophthalmic microsurgery capability.
On the day of service, the patient undergoes general anesthesia. A vitreoretinal surgeon performs a standard 25- or 23-gauge pars plana vitrectomy followed by a subretinal injection of J3398 (voretigene neparvovec-rzyl), dosed per manufacturer instructions (one vial per treated eye as appropriate). Typical adjunct intraoperative steps include creation of a localized retinal detachment (bleb) and careful air-fluid exchanges; intraoperative imaging or indirect ophthalmoscopy confirms subretinal placement. Postoperative care includes topical antibiotics and steroids, positioning instructions as indicated, and scheduled follow-up visits to monitor visual function, intraocular pressure, and potential immune or inflammatory responses. Billing captures the drug with J3398 and may include concomitant surgical CPT codes for vitrectomy and subretinal injection, anesthesia charges, and facility services. Patient scenarios often involve modifier use for bilateral procedures, unusual procedural services, or professional/facility distinctions according to payer rules.
Coding Specifications
| Modifier |
|---|